Genetic Technologies Ltd
NASDAQ:GENE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (22.8), the stock would be worth $-5 924.51 (408% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -7.4 | $1 921.8 |
0%
|
| Industry Average | 22.8 | $-5 924.51 |
-408%
|
| Country Average | 16.5 | $-4 300.15 |
-324%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Genetic Technologies Ltd
NASDAQ:GENE
|
52.1m USD | -7.4 | -5.4 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 1 226.4 | 4 280.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
193.4B USD | 18.2 | 26 | |
| US |
|
Danaher Corp
NYSE:DHR
|
130.1B USD | 17.6 | 34.4 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 30.1 | 46.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
34.9B CHF | 16.6 | -122.3 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
296.1B CNY | 16.2 | 15.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.1B USD | 18.4 | 25 | |
| US |
|
Waters Corp
NYSE:WAT
|
32.8B USD | 30.9 | 47.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.7B USD | 11.4 | 20.1 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.7B USD | 21.7 | 29.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 16.5 |
| 70th Percentile | 24.5 |
| Max | 6 797.5 |
Other Multiples
Genetic Technologies Ltd
Glance View
Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company is headquartered in Melbourne, Victoria. The firm is focused on the development and commercialization of genetic risk assessment technology. The firm is engaged in providing genomics-based tests in health, wellness and serious disease through its GeneType and EasyDNA brands. GTG is focused on developing an integrated predictive genetic testing and assessment tools enabling medical practitioners and their patients to proactively manage health. The Company’s geneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and type two diabetes in a single test. The GeneType offers integrated risk testing for a range of serious conditions. GTG offers cancer predictive testing and assessment tools for physicians. Its Polygenic Risk Scores (PRS) platform offers integrated clinical and genetic risk delivering actionable outcomes from physicians and individuals.
